Biotech News

Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease

Prime Medicine (PRME)Prime Medicine2026-06-18 12:00 ESTClinical readout

-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America and Europe -- -- Initiation of Phase 1/2 clinical trial expected in second half of 2026; initial

Prime Medicine

Prime Editing Prime Medicine develops genetic medicines using Prime Editing, a technology designed to make precise DNA changes without requiring double-strand breaks. Its programs target diseases that may be addressed by correcting pathogenic variants in vivo or ex vivo. PM577 PM577 is an in vivo Prime Editing candidate designed to...

Recent company news

PRMEPrime Medicine2026-08-06 12:00 EST

Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates

PRMEPrime Medicine2026-07-23 20:05 EST

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease

PRMEPrime Medicine2026-07-08 12:00 EST

Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics

PRMEPrime Medicine2026-06-22 12:00 EST

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

PRMEPrime Medicine2026-06-18 12:00 EST